Preparation and immunological evaluation of oral solution of egg yolk-derived hepatitis B virus-specific transfer factor
10.3969/j.issn.1673-4254.2013.12.26
- VernacularTitle:鸡卵黄乙型肝炎特异性转移因子口服液的制备及其免疫活性鉴定
- Author:
Yanping XU
1
;
Qing ZHANG
;
Xuejun ZHAN
;
Daze XIE
;
Ge DAI
;
Hui YANG
Author Information
1. 江西省医学科学研究院
- Keywords:
egg yolk;
transfer factor;
hepatitis B virus;
oral solution
- From:
Journal of Southern Medical University
2013;(12):1827-1830
- CountryChina
- Language:Chinese
-
Abstract:
Objective To prepare the oral solution of egg yolk hepatitis B virus (HBV)-specific transfer factor (EYHBV-TF) and evaluate its immunological activity as an immune regulator against hepatitis B. Methods From hens immunized with the Hepatitis B vaccine the egg yolk was isolated to extract the specific transfer factor EYHBV-TF, and its physicochemical properties were examined. Leukocyte adhesion inhibition test (LAI) was performed to detect the immunogenic activity of EYHBV-TF. The solution of EYHBV-TF was then administered orally in normal mice, and the specific cellular immune activity induced was assayed with delayed type skin hypersensitivity test (DTH), with the non-specific immune activity assessed with immune organ index. The immune responses induced by oral EYHBV-STF solution were compared with those by EYHBV-STF injection and by different dosages (injection and oral) of porcine spleen HBV-specific transfer factor (PSHBV-STF), porcine spleen nonspecific transfer factor, and egg yolk extracts from non-immunized hens. Results The prepared EYHBV-STF oral solution, which met the standards for biological products, could inhibit leukocyte adhesion in vitro and significantly enhance mouse foot pad swelling, demonstrating its capability of transferring antigen-specific delayed type hypersensitivity reactions to naive recipient. EYHBV-STF oral solution also significantly improved the immune organ index in mice (P<0 01) with similar effects to those caused by EYHBV-STF injections and by PSHBV-STF injection and oral solution. Conclusion Orally administered EYHBV-STF and EYHBV-STF injection both possess hepatitis B antigen-specific cellular immune activity and can significantly enhance specific cellular immune responses.
